The United States Food and Drug Administration (FDA) revealed on Friday its latest study found Pfizer Inc. and BioNTech SE's vaccine against COVID-19 is 90.7% effective against the disease in children aged between five and 11, APA reports citing Teletrader.
The trials were conducted in 2,268 individuals divided into two groups. Those that received both doses of the jab developed an immunity of 90.7% in comparison to those that got a placebo.
Pfizer asked for the FDA's approval for the use of its treatment in kids earlier this month.
Follow us on Telegram
t.me/apanewsaz
Follow us on Instagram
Follow us on Facebook
Follow us on Twitter
